{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269442","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.289919+00:00","generated_at":"2026-05-16T23:51:42.369273+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IN8bio Q3 net loss $3.9M ($0.85/share); cash $10.7M; INB-619/100 updates","bullets":["Net loss of $3.9M in Q3 2025 vs $7.1M in Q3 2024; basic and diluted EPS -$0.85 vs -$4.49.","R&D expenses $2.1M (down from $3.3M); G&A $1.9M (down from $2.7M) due to cost-saving measures.","Cash $10.7M as of Sep 30, 2025, up from $4.0M year-over-year.","INB-619 preclinical data at ACR showed B cell elimination similar to blinatumomab/mosunetuzumab with minimal cytokine release.","INB-100 Phase 1 trial expanded to The Ohio State University to accelerate enrollment; updated GBM data planned at SNO Nov 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269442","json":"https://secwatch.observer/filing/0001193125-25-269442.json","markdown":"https://secwatch.observer/filing/0001193125-25-269442.md","text":"https://secwatch.observer/filing/0001193125-25-269442.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312525269442/0001193125-25-269442-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312525269442/inab-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:51:42.369273+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}